Please assess the completion status of the following clinical trial:

Trial Title: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 years and above;~* Histologically or cytologically documented adenocarcinoma of the colon or rectum;~* Metastatic disease;~* Measurable disease or assessable but nonmeasurable disease allowed;~* ECOG 0-1~* No prior oxaliplatin or bevacizumab.~* No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed;~* No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier);~* No bleeding diathesis or coagulopathy~* Adequate renal and hepatic functions as per protocol;~* Signed informed consent~Exclusion Criteria:~* Clinically significant cardiovascular or peripheral vascular disease;~* Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin;~* Serious non-healing wound, ulcer, or bone fracture;

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).